Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0392326 (discomfort)
 22,423 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ankylosing spondylitis is a systemic rheumatic disorder characterized by inflammation of the spine, sacroiliac, and large peripheral joints. Effective management demands both immediate and long-term objectives. The physician must first relieve joint inflammation and discomfort with nonsteroidal anti-inflammatory drugs, then begin long-range planning with daily exercise and other supportive measures to prevent, delay, or correct deformity. Diclofenac sodium, a nonsteroidal anti-inflammatory drug that is used worldwide in ankylosing spondylitis, has not yet been marketed in the United States. This article highlights two American studies with diclofenac: (1) a short-term, double-blind comparison with indomethacin, and (2) a 38-week extension with diclofenac for long-term efficacy and safety data. The results of these trials demonstrate diclofenac to be effective and safe for both short- and long-term treatment. When compared with indomethacin, a standard reference drug in trials of ankylosing spondylitis, diclofenac was comparable in efficacy but had a more favorable side-effect profile.
 ...
PMID:Efficacy of diclofenac in ankylosing spondylitis. 351 35

Two prospective, randomized, double-masked studies were conducted evaluating the analgesic effect of topical eyedrops after radial keratotomy (RK). One study of 117 consecutive initial RK procedures compared topical ketorolac (Acular) with topical diclofenac (Voltaren), and another study of 23 consecutive initial RK procedures compared topical ketorolac with a control medication (HypoTears). Topical ketorolac was significantly more effective than the control but not significantly different from topical diclofenac. The onset of analgesic effect of these topical nonsteroidal anti-inflammatory drugs is longer than one hour. The analgesic effect of oral acetaminophen #3 significantly augments that of topical diclofenac drops for those experiencing any discomfort by six hours after surgery.
 ...
PMID:Relative effectiveness of topical ketorolac and topical diclofenac on discomfort after radial keratotomy. 779 Oct 55

The eyes of 65 consecutive radial keratotomy patients were treated topically with either diclofenac sodium 0.1% (Voltaren) solution or with Tears Naturale (control group) preoperatively and postoperatively in a prospective, randomized, double-masked study. During the first postoperative day, patients completed a questionnaire on discomfort level present at 15 minutes and at one, three, six, and 18 hours after surgery. Patients treated with topical diclofenac were generally more comfortable than patients in the control group. They had a significantly lower rate of "moderate" or "severe" discomfort and a higher rate of less than "mild" discomfort. Peak discomfort occurred at three hours in both groups. The prescribed optional oral analgesic was taken by 48.5% of patients in the diclofenac group and by 71.9% of those in the control group.
 ...
PMID:Effect of topical diclofenac solution on discomfort after radial keratotomy. 793 24

Actinic Keratoses (AKs) are epidermal skin lesions that have the potential to develop into squamous cell carcinoma. Many of the treatment options available can cause discomfort, pain or skin irritation. Topical 3% diclofenac in 2.5% hyaluronan gel (Solaraze, Bioglan Pharma) is a relatively new treatment that has been shown to be effective and well tolerated for the treatment of AKs.
 ...
PMID:Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. 1471 39

The aim of the study was to compare treatment with diclofenac sodium (Voltaren 3 x 50 mg) to occlusal splint therapy in a randomized, single-blind controlled trial of patients with a diagnosis of temporomandibular joint (TMJ) osteoarthritis (OA) in accordance with Research Diagnostic Criteria for temporomandibular disorders. Patients with general joint disorders or restrictions against medication with non-steroidal anti-inflammatory drug were not included. Twenty-seven females and two males (aged 36-76 years) included, answered a standardized questionnaire and were clinically examined and they underwent TMJ tomography. The treatment was randomized to either splint (n = 15) or diclofenac (n = 14). The temperatures over the TMJs were determined. The patients were re-examined 1 week, 1 month and 3 months after the start of treatment. A 1-year follow-up was carried out using questionnaires. After 1 week of treatment with diclofenac, significant reductions of pain and discomfort, TMJ tenderness and joint pain on jaw movements were noted. The splint therapy gave a significant reduction of reported symptoms after 1 month of treatment. Both treatments gave few adverse effects and were on an equal level. Estimation of the degree of inflammation by measuring the surface temperature over the TMJ was not reliable. Structural changes of the symptomatic TMJs were radiographically found in 82%, the contralateral, symptom-free TMJ had changes in 36%. There was a discrepancy between the clinical and the radiographical findings. Diclofenac gave a more rapid improvement, but both treatments gave a significant reduction of symptoms of TMJ OA within 3 months which remained at the one-year follow-up.
 ...
PMID:Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. 1848 50

Interest is increasing in the use of sequential or combined therapeutic modalities for spot or area treatment of actinic keratoses (AKs) to achieve complete sustained remission. For multiple lesions in a contained area, topical treatment offers less discomfort, better cosmesis and greater patient convenience than destructive/ablative techniques. Twelve patients with multiple grade I and II AK lesions of the scalp (cases 1-10) or the dorsum of the hand (cases 11 and 12), most with a history of recurrence, were treated with Solaraze gel (3% diclofenac sodium in 2.5% hyaluronic acid) twice daily for 12 weeks, followed by a 2-week treatment-free interval, then Actikerall cutaneous solution (5-fluorouracil 5 mg/g and salicylic acid 100 mg/g) once daily for up to 6 weeks as required. Sequential treatment provided complete (clinical and histological) clearance in 8/10 male patients. Two patients with numerous lesions had partial clearance (significant improvement) and the remaining few lesions were treated with erbium laser. Both female patients achieved complete clinical clearance with sequential treatment. Solaraze/Actikerall were well tolerated. A case of contact dermatitis with Solaraze resolved after discontinuation and the patient progressed to treatment with Actikerall. Local application site reactions resolved upon treatment completion. Topical lesion-directed sequential treatment with Solaraze/Actikerall is a rational approach to treat patients with multiple AKs. Sequential treatment produces excellent clearance rates which are accompanied by relevant improvement in patients' quality of life.
...
PMID:Sequential treatment of multiple actinic keratoses with solaraze and actikerall. 2512 Apr 67